Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
You can also access detailed information by clicking Login in the website header.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
Germany
Regulatory Approval:
N/A
Your Trustedworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Vanflyta (quizartinib) is a kinase inhibitor approved for adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive, used in combination with standard cytarabine and anthracycline induction and cytarabine consolidation chemotherapy, and as maintenance monotherapy following consolidation chemotherapy.
Vanflyta selectively inhibits FLT3 receptor tyrosine kinase, blocking abnormal signaling driven by the FLT3-ITD mutation that is present in a significant subset of AML patients and is associated with a more aggressive disease course.
Vanflyta is intended for newly diagnosed AML patients confirmed to carry a FLT3-ITD mutation through an approved test, used across the induction, consolidation, and maintenance phases of treatment.
Dosing varies by treatment phase: 35.4 mg once daily during induction and consolidation, and 26.5 mg once daily for the first 14 days of maintenance followed by 53 mg once daily thereafter, as directed by the treating hematologist-oncologist.
Boxed Warning — Vanflyta: Vanflyta can cause QT interval prolongation, Torsades de Pointes, and cardiac arrest. Vanflyta is available only through a restricted distribution program that requires ECG and electrolyte monitoring due to these risks.
Electrolyte abnormalities, particularly hypokalemia and hypomagnesemia, should be corrected before starting treatment. Regular ECG monitoring is required throughout therapy.
Vanflyta is contraindicated in patients with severe electrolyte abnormalities or congenital long QT syndrome, and should be avoided with concomitant QT-prolonging medicines where possible.
Dose reduction is required when Vanflyta is used with strong CYP3A inhibitors; a treating physician should review all concomitant medicines before starting therapy.
Vanflyta may cause fetal harm. Effective contraception should be used during treatment.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Vanflyta is manufactured and marketed by Daiichi Sankyo Europe GmbH. It is sourced through authorized distribution channels for patients seeking named-patient import into India.
Patients typically need a valid prescription from a treating hematologist-oncologist confirming newly diagnosed AML and FLT3-ITD mutation testing results. NPP's regulatory team assists in preparing and verifying the documentation needed for a compliant import.
As an approved therapy for FLT3-ITD-positive AML, Vanflyta is sourced through authorized channels and imported under GDP-compliant logistics to preserve product quality throughout transit.
NPP sources Vanflyta directly from authorized pharmaceutical distributors to ensure product authenticity and full traceability. Every shipment is handled under Good Distribution Practice (GDP) conditions from origin to the patient's doorstep.
Vanflyta should be stored at 20°C to 25°C, with excursions permitted between 15°C and 30°C, and this condition is maintained throughout transit.
Once documentation and regulatory approvals are in place, delivery timelines are communicated transparently at the time of quotation, accounting for import clearance and last-mile logistics to the patient's city.
Patients across India can access Vanflyta through NPP's regulated import pathway, with hematology-oncology specialists in major cities supporting the treatment process.
Leading hospitals in Mumbai support hematology-oncology care coordination and documentation for Vanflyta access.
Delhi's major hospitals assist patients with prescription support and documentation for Vanflyta.
Bangalore's specialist network offers access coordination for eligible AML patients seeking Vanflyta.
Chennai-based hematology specialists coordinate Vanflyta access alongside comprehensive AML care.
Hyderabad's care institutions support patients pursuing Vanflyta therapy.
Kolkata's specialist centers help coordinate documentation and treatment access for Vanflyta.
Pune-based specialists assist with prescription support and Vanflyta treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Vanflyta.
Kochi's specialist units assist patients with the documentation needed for Vanflyta access.
Chandigarh's care centers support Vanflyta treatment coordination for patients from North India.
Jaipur's specialists help patients navigate the Vanflyta access process.
Lucknow-based centers assist patients pursuing Vanflyta therapy.
Bhubaneswar's institutions support access to Vanflyta for eligible patients.
Guwahati's specialists help coordinate Vanflyta access for patients across the Northeast.
Patients in other cities across India can also access Vanflyta through NPP's nationwide coordination network.
Written By: Nitin Goswami, Senior Medical Content Writer
Last Updated: 15 September 2026
Sources: FDA
Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Last Updated: 15 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
